Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Adial Pharmaceuticals, Inc. (ADIL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5879-0.0007 (-0.12%)
At close: 04:00PM EDT
0.6172 +0.03 (+4.98%)
After hours: 05:26PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Previous Close0.5886
Open0.5900
Bid0.5800 x 1300
Ask0.6300 x 800
Day's Range0.5520 - 0.6119
52 Week Range0.4500 - 5.0800
Volume191,311
Avg. Volume732,085
Market Cap15.082M
Beta (5Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)-0.8580
Earnings DateMay 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADIL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adial Pharmaceuticals, Inc
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    7 months agoMorningstar
View more
  • GlobeNewswire

    Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

    AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinking AD04 demonstrated statistically significant difference in AUD severity, as compared to placebo, with an 84% decrease in the number of heavy drinking patients meeting the criteria for AUD diagnosis Company plans to submit ONWARD results to both European and U.S. regulatory agencies Conference call

  • Benzinga

    EXCLUSIVE: Adial Pharma's AD04 Effective In Heavy Drinker Alcohol Use Disorder Patients

    Adial Pharmaceuticals Inc's (NASDAQ: ADIL) ONWARD Phase 3 study of AD04 for Alcohol Use Disorder (AUD) achieved a statistically significant mean reduction in heavy drinking days compared to placebo. Trial Results: AD04 achieved a statistically significant mean reduction compared to placebo from baseline at month six in heavy drinking days among "heavy drinkers" (average <10 drinks per drinking day), accounting for around two-thirds of the trial population. A similar trend was seen in the combine

  • GlobeNewswire

    Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder

    Company to host conference call on Wednesday, July 20, 2022, at 1 PM ETCHARLOTTESVILLE, Va., July 18, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it plans to report topline results from the Company’s ONWARD™ Phase 3 clinical trial on Wednesday, July 20, 2022. The Company plan

Advertisement
Advertisement